Debt-to-equity of Protagenic Therapeutics, Inc.\new from 31 Mar 2015 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Protagenic Therapeutics, Inc.\new quarterly Debt-to-equity in % history and change rate from 31 Mar 2015 to 31 Dec 2025.
Protagenic Therapeutics, Inc.\new Debt-to-equity for the quarter ending 31 Dec 2025 was -200%, a 554% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Protagenic Therapeutics, Inc.\new Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	-200%	-169%	-554%	31 Dec 2025
Q3 2025	-154%	-45%	-41%	30 Sep 2025
Q2 2025	-117%	-189%	-264%	30 Jun 2025
Q1 2025	-60%	-94%	-276%	31 Mar 2025
Q4 2024	-31%	-54%	-228%	31 Dec 2024
Q3 2024	-109%	-132%	-586%	30 Sep 2024
Q2 2024	71%	+53%	+293%	30 Jun 2024
Q1 2024	34%	+20%	+146%	31 Mar 2024
Q4 2023	24%	+12%	+95%	31 Dec 2023
Q3 2023	23%	+11%	+102%	30 Sep 2023
Q2 2023	18%	-7.4%	-29%	30 Jun 2023
Q1 2023	14%	-11%	-44%	31 Mar 2023
Q4 2022	12%	-57%	-82%	31 Dec 2022
Q3 2022	11%	+261%		30 Sep 2022
Q2 2022	26%	-87%	-77%	30 Jun 2022
Q1 2022	25%	+195%		31 Mar 2022
Q4 2021	70%	+285%		31 Dec 2021
Q3 2021	-250%	-15%	-6.5%	30 Sep 2021
Q2 2021	113%			30 Jun 2021
Q1 2021	-170%			31 Mar 2021
Q4 2020	-215%			31 Dec 2020
Q3 2020	-235%			30 Sep 2020
Q4 2015	-136%			31 Dec 2015
Q3 2015	-163%			30 Sep 2015
Q2 2015	-205%			30 Jun 2015
Q1 2015	-294%			31 Mar 2015

* An asterisk sign (*) next to the value indicates that the value is likely invalid.